Nautilus Biotechnology, Inc. — Form SCHEDULE 13D/A
Filed August 14, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Perceptive Advisors LLC filed an amended Schedule 13D for Nautilus Biotechnology, Inc. on August 14, 2026. The filing document itself does not display the specific shareholding percentages, share counts, or dollar amounts of the amended position in the provided text; only the filing metadata and filer/subject entity information are visible. Without access to the substantive amendment details, the nature and magnitude of the ownership change cannot be determined from this submission.
Why this rating
Schedule 13D amendments are routine regulatory disclosures. Without specific ownership %, share count, or transaction details visible, cannot assess materiality relative to $35.8M market cap.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.